Bridging science and technology: a biotech CEO’s perspective
Drug Target Review
OCTOBER 14, 2024
His current role at Mironid focuses on developing treatments for rare genetic kidney diseases, and his insights reveal the challenges and potential of integrating advanced technologies like artificial intelligence (AI) into the drug discovery process. Raminderpal earned his PhD in semiconductor modelling in 1997.
Let's personalize your content